SYRS (OTC)
SYROS PHARMACEUTICALS INC
$0.000200
-0.000600 (-75.00%)
Prev close: $0.000800
Company Information
- Exchange
- OTC Link
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Nancy A. Simonian
- Asset Type
- otc
- Website
- —
Fundamentals
- Market Cap
- $0.01M
- Employees
- 124
- P/E (TTM)
- —
- P/B (TTM)
- 1.49
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
0
Strong Buy
0
Buy
3
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2024 (Q3)
|
$-0.16 | $-0.73 | +0.5744 | +78.21% |
|
Jun 2024 (Q2)
|
$-0.59 | $-0.78 | +0.1932 | +24.67% |
|
Mar 2024 (Q1)
|
$-0.10 | $-0.89 | +0.7862 | +88.72% |
|
Dec 2023 (Q4)
|
$-2.18 | $-1.17 | -1.0125 | -86.72% |
Financial Statements
| Revenues | $386.00K |
| Operating Expenses | $112.05M |
| Research and Development | $88.64M |
| Other Operating Expenses | $23.41M |
| Operating Income/Loss | -$111.66M |
| Income/Loss From Continuing Operations After Tax | -$97.82M |
| Income/Loss From Continuing Operations Before Tax | $76.70M |
| Net Income/Loss | -$97.82M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$97.82M |
| Net Income/Loss Available To Common Stockholders, Basic | -$97.82M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.07 |
| Diluted Earnings Per Share | -$3.07 |
| Basic Average Shares | 117,993,080 |
| Diluted Average Shares | 117,993,080 |
| Assets | $85.00M |
| Current Assets | $63.93M |
| Noncurrent Assets | $21.06M |
| Fixed Assets | $6.31M |
| Other Non-current Assets | $14.76M |
| Liabilities | $96.12M |
| Current Liabilities | $28.39M |
| Accounts Payable | $9.65M |
| Wages | $4.79M |
| Other Current Liabilities | $13.96M |
| Noncurrent Liabilities | $67.73M |
| Equity | -$11.12M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$11.12M |
| Liabilities And Equity | $85.00M |
| Net Cash Flow From Operating Activities | -$100.02M |
| Net Cash Flow From Operating Activities, Continuing | -$100.02M |
| Net Cash Flow From Investing Activities | $1.95M |
| Net Cash Flow From Investing Activities, Continuing | $1.95M |
| Net Cash Flow From Financing Activities | $43.16M |
| Net Cash Flow From Financing Activities, Continuing | $43.16M |
| Net Cash Flow | -$54.91M |
| Net Cash Flow, Continuing | -$54.91M |
| Comprehensive Income/Loss | -$97.82M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$97.82M |
| Other Comprehensive Income/Loss | $0.00 |